Modern Diagnostic & Research Centre Ltd Management Discussions

Economic and Industry Overview

The Indian healthcare industry continues to witness structural growth, supported by increasing healthcare awareness, rising disposable incomes, greater health-insurance penetration, urbanisation and the increasing prevalence of lifestyle-related and chronic diseases. Within healthcare, diagnostics remains an important and relatively resilient segment, as diagnostic testing plays a critical role in disease detection, prevention, treatment planning and ongoing disease management.

The Indian diagnostics market continues to be characterised by a large unorganised component alongside an expanding organised diagnostic-chain segment. Organised players are increasingly strengthening their laboratory infrastructure, collection networks and digital capabilities to improve accessibility and turnaround time. The industry is also witnessing increasing adoption of preventive health check-ups, specialised testing, home sample collection and technology-enabled diagnostic services.

The medium-term outlook for the industry remains favourable, supported by increasing diagnostic penetration in Tier-II, Tier-III and semi-urban markets, greater awareness of preventive healthcare and the growing need for regular monitoring of chronic diseases. At the same time, competition is intensifying, including from new digital healthcare platforms and technology-led service providers.

2. Business Overview

The Company is engaged in the business of providing diagnostic and pathology services to individuals, healthcare institutions, doctors, corporates and other institutional customers. Its service portfolio comprises routine pathology testing, specialised diagnostics, preventive health packages and other diagnostic investigations, as applicable to its business model.

The Company operates through a network of laboratories, diagnostic centres, collection centres and/or home-collection facilities. Its hub-and-spoke operating model enables centralised processing of samples while providing convenient access to customers across multiple geographies.

The Company continues to focus on strengthening its geographic presence, expanding its test menu, improving customer experience and increasing the penetration of specialised and preventive diagnostics. These initiatives are intended to support sustainable revenue growth while improving operating leverage and asset utilisation.

3. Operational Performance

During the year under review, the Company continued to focus on increasing patient reach, sample volumes and revenue per patient. Growth was supported by a combination of volume expansion, improved test mix, increased adoption of preventive healthcare services and expansion of the Companys network.

The Company continued to invest in laboratory capabilities, technology, quality systems and customer-facing infrastructure. The expansion of the network is expected to improve accessibility and create additional opportunities for capturing diagnostic demand in underpenetrated markets.

4. Financial Performance

The Companys financial performance during the year reflects the underlying growth in diagnostic demand and the Companys continued focus on operational efficiency.

Particulars	FY [Current Year]	FY [Previous Year]	Change (in %)
Revenue from Operations	8,413.72	7,880.45	6.77%
EBITDA	1,361.74	1,891.38	-28%
EBITDA Margin	16.18%	24.00%
Profit Before Tax	599.13	1,286.95	-53.45%
Profit After Tax	525.34	900.77	-41.68%
PAT Margin	6.24%	11.43%

Revenue growth was primarily supported by higher testing volumes, expansion of the Companys network, improved realisation and a favourable service mix. The Company continued to focus on increasing the contribution of specialised and value-added diagnostics, which can support higher realisations and strengthen customer engagement.

Profitability remained dependent on the Companys ability to achieve operating leverage, optimise laboratory utilisation, control employee and logistics costs and maintain an appropriate balance between growth investments and operating efficiency.

5. Business Strategy and Growth Initiatives

The Companys growth strategy is focused on the following key areas:

Expansion into underserved markets:

The Company intends to increase its presence in Tier-II, Tier-III and other emerging markets where diagnostic penetration remains relatively low. Expansion through laboratories, collection centres, partnerships and hub-and-spoke infrastructure can enable the Company to reach a broader customer base.

Preventive healthcare:

Growing awareness regarding early detection is creating opportunities in preventive health packages, wellness screening and periodic health monitoring. The Company intends to strengthen its preventive-health portfolio and develop customised diagnostic solutions for different customer segments.

Specialised diagnostics:

The Company continues to expand its specialised testing capabilities, including advanced pathology, molecular diagnostics, genetic testing and other high-value diagnostic services, where commercially and operationally appropriate.

Digital transformation:

Digital platforms are increasingly important for test booking, home collection, report delivery, customer communication and healthcare engagement. The Company continues to evaluate technology and artificial-intelligence applications that can improve operational efficiency, diagnostic workflows and customer experience. The diagnostic industry is increasingly adopting digital technologies and AI-enabled solutions.

Network optimisation:

Management remains focused not only on expanding the network but also on improving productivity and utilisation of existing laboratories and collection infrastructure. Better utilisation can provide operating leverage and support margin improvement as volumes increase.

Strategic partnerships and acquisitions:

The Company may evaluate strategic partnerships, acquisitions and other inorganic opportunities where such initiatives provide access to new geographies, capabilities, technology, customer segments or specialised diagnostic offerings.

6. Human Resources

People remain an important component of the Companys operations. The Company depends on qualified medical professionals, pathologists, technicians, laboratory personnel, customer-service teams and managerial talent to maintain service quality and operational efficiency.

During the year, the Company continued to focus on employee training, technical capability development, leadership development, workplace safety and employee engagement. The Company believes that continuous investment in human capital is essential to maintaining diagnostic quality and delivering a consistent customer experience.

7. Quality and Patient Experience

Diagnostic accuracy, reliability and turnaround time are fundamental to the Companys business. The Company therefore continues to strengthen quality-control processes, laboratory protocols, equipment calibration, accreditation standards and internal monitoring systems.

The Company also remains focused on improving customer convenience through digital booking, home sample collection, online report access and other technology-enabled services. Maintaining high standards of quality and patient experience is expected to remain a key differentiator in an increasingly competitive market.

8. Risk and Mitigation

The principal risks faced by the Company include:

Competitive risk:

The diagnostics sector remains competitive, with established diagnostic chains, hospitals, standalone laboratories and emerging digital healthcare platforms competing for customers. The Company seeks to mitigate this risk through brand strength, quality, network reach, specialised capabilities and customer service.

Pricing pressure:

Competition may result in discounts and pricing pressure, particularly in routine pathology testing. The Company seeks to offset such pressure through volume growth, differentiated services, specialised testing and operational efficiency.

Regulatory risk:

Changes in healthcare regulations, accreditation requirements, data protection requirements and other applicable laws could affect operations. The Company monitors regulatory developments and maintains appropriate compliance systems.

Operational risk:

Diagnostic operations require reliable equipment, trained personnel, efficient logistics and robust information systems. Equipment downtime, sample transportation issues or system disruptions could adversely affect turnaround times and customer experience.

Technology and cybersecurity risk:

Increasing reliance on digital platforms and patient data creates cybersecurity and data-protection risks. The Company continues to strengthen information-security controls and technology infrastructure.

Reputational and quality risk:

Any significant error or inconsistency in diagnostic reporting may adversely affect patient trust and the Companys reputation. Accordingly, quality assurance, internal controls and professional oversight remain critical components of the Companys operating framework.

9. Internal Controls

The Company has established internal control systems commensurate with the size and complexity of its operations. These controls cover financial reporting, operational processes, asset safeguarding, regulatory compliance, information technology and risk management.

Internal and statutory audits are undertaken periodically, with observations and recommendations reviewed by the appropriate management and Board-level committees. Management believes that the Companys internal financial controls are adequate and operating effectively.

Outlook The Company remains cautiously optimistic about the medium- to long-term prospects of the diagnostic industry. Increasing healthcare awareness, the rising burden of chronic and lifestyle-related diseases, preventive healthcare adoption and improving access to healthcare services provide structural growth opportunities. The industry is also expected to benefit from greater penetration of organised diagnostic chains in smaller cities and towns. The Companys priorities for the coming period will include increasing testing volumes, strengthening its geographic footprint, expanding specialised diagnostics, improving preventive-health offerings, leveraging technology and maintaining operational discipline. Management will continue to balance investments in growth with profitability, cash generation and prudent capital allocation. While competitive intensity and pricing pressures remain key considerations, the Company believes that its established network, diagnostic capabilities, customer relationships and focus on quality provide a sound foundation for sustainable growth.

11. Cautionary Statement

Cautionary Statement Statements in this Management Discussion and Analysis describing the Companys objectives, projections, estimates, expectations or other forward-looking information may constitute forward-looking statements within the meaning of applicable securities laws and regulations. Such statements are based on managements current expectations and assumptions and are subject to various risks and uncertainties. Actual results may differ materially from those expressed or implied by such statements due to changes in economic conditions, industry dynamics, regulatory requirements, competitive environment, technological developments and other factors beyond the Companys control.